By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



BiopĂ´le III
Route de la Corniche 9B
  Epalinges  CH-1066  Switzerland
Phone: 41-21-651-92-20 Fax: 41-21-651-92-21



Company News
Anergis Announces Completion Of Treatment In AllerT Phase II Dose-Ranging Trial 4/1/2015 9:27:07 AM
Anergis Presents Sustained Efficacy Data From Its Allert Phase 2b Trial At The AAAAI Annual Meeting 2/23/2015 10:50:02 AM
Anergis Granted U.S. Patent For Ragweed Allergy Vaccine AllerR 12/19/2014 10:41:18 AM
Anergis Starts Phase II Dose Ranging Trial With Birch Pollen Allergy Vaccine AllerT 12/11/2014 6:40:00 AM
Anergis Reports Positive Long-Term Clinical Efficacy Of Lead Compound AllerT 9/16/2014 11:33:21 AM
Anergis Appoints Dr. Vanya Beltrami As Director Product Development 6/3/2014 10:05:05 AM
Anergis To Present New COP Allergy Vaccine Data At European Academy of Allergology and Clinical Immunology Conference 2014 In Copenhagen 5/27/2014 1:34:43 PM
Anergis Completes Enrolment In The Long-Term Efficacy Trial Of Lead Compound AllerT 4/23/2014 11:26:33 AM
Phase 2b Results Of Anergis' Lead Compound Allert To Be Presented At 2014 American Academy of Dermatology Annual Meeting In San Diego 2/27/2014 8:14:27 AM
Anergis Closes Financing Round Totaling CHF 8 Million 2/5/2014 6:04:14 AM